tiprankstipranks
Regencell Bioscience (RGC)
NASDAQ:RGC
US Market

Regencell Bioscience (RGC) Financial Statements

11 Followers

Regencell Bioscience Financial Overview

Regencell Bioscience's market cap is currently ―. The company's EPS TTM is $-0.451; its P/E ratio is -9.97; Regencell Bioscience is scheduled to report earnings on ―, and the estimated EPS forecast is $―. See an overview of income statement, balance sheet, and cash flow financials.
Jun 23Jun 22Dec 21Jun 21Dec 20
Income Statement-
Total Revenue-----
Gross Profit-----
EBIT-----
EBITDA-----
Net Income Common Stockholders-----
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments$ 11.56M$ 16.42M$ 0.00$ 59.41K$ 305.96K
Total Assets$ 12.62M$ 18.02M$ 21.06M$ 340.13K$ 600.37K
Total Debt$ 463.67K$ 771.25K$ 0.00$ 3.68M$ 3.54M
Net Debt$ -11.10M$ -15.65M$ 0.00$ 3.62M$ 3.24M
Total Liabilities$ 632.32K$ 938.03K$ 1.36M$ 4.34M$ 3.59M
Stockholders Equity$ 12.03M$ 17.07M$ 19.70M$ -4.00M$ -2.98M
Cash Flow-
Free Cash Flow-----
Operating Cash Flow-----
Investing Cash Flow-----
Financing Cash Flow-----
Currency in USD

Regencell Bioscience Earnings and Revenue History

Regencell Bioscience Debt to Assets

Regencell Bioscience Cash Flow

Regencell Bioscience Forecast EPS vs Actual EPS

Currently, no data available
Please return soon. This page is being updated.
What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis